Patents Assigned to PAR Pharmaceutical, Inc.
-
Patent number: 9925234Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.Type: GrantFiled: August 28, 2017Date of Patent: March 27, 2018Assignee: PAR PHARMACEUTICAL, INC.Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
-
Patent number: 9919026Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.Type: GrantFiled: August 28, 2017Date of Patent: March 20, 2018Assignee: PAR PHARMACEUTICAL, INC.Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
-
Patent number: 9750785Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.Type: GrantFiled: February 7, 2017Date of Patent: September 5, 2017Assignee: PAR PHARMACEUTICAL, INC.Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
-
Patent number: 9744239Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.Type: GrantFiled: May 20, 2015Date of Patent: August 29, 2017Assignee: PAR PHARMACEUTICAL, INC.Inventors: Matthew Kenney, Vinayagam Kannan
-
Patent number: 9744209Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.Type: GrantFiled: February 7, 2017Date of Patent: August 29, 2017Assignee: PAR PHARMACEUTICAL, INC.Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
-
Patent number: 9687526Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.Type: GrantFiled: October 10, 2016Date of Patent: June 27, 2017Assignee: PAR PHARMACEUTICAL, INC.Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
-
Patent number: 9415007Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.Type: GrantFiled: September 12, 2014Date of Patent: August 16, 2016Assignee: PAR PHARMACEUTICAL, INC.Inventors: Steven C. Quay, Peter C. Aprile, Zenaida O. Go, Anthony P. Sileno
-
Patent number: 9375478Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.Type: GrantFiled: May 20, 2015Date of Patent: June 28, 2016Assignee: PAR PHARMACEUTICAL, INC.Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
-
Patent number: 9295657Abstract: Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.Type: GrantFiled: August 4, 2015Date of Patent: March 29, 2016Assignee: Par Pharmaceutical, Inc.Inventors: Vinayagam Kannan, Patrick Irish, Michael Bergren
-
Patent number: 9186374Abstract: The present invention relates generally to vitamin B12 nasal spray compositions and methods of using the same in the treatment of vitamin B12 deficiency and various disorders that are related to such deficiency. In particular embodiments, the present invention is directed to treatment methods comprising intranasal administration of a cobalamin composition according to a particular dosing and frequency schedule and to a preservative-free nasal spray composition comprising a cobalamin compound useful in the practice of such treatment methods.Type: GrantFiled: November 13, 2009Date of Patent: November 17, 2015Assignee: Par Pharmaceutical, Inc.Inventors: Theodore H. Feller, Angela Sutterer, Patrick J. Arnall
-
Patent number: 9119876Abstract: Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.Type: GrantFiled: March 13, 2015Date of Patent: September 1, 2015Assignee: PAR PHARMACEUTICAL, INC.Inventors: Vinayagam Kannan, Patrick Irish, Michael Bergren
-
Patent number: 8940714Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.Type: GrantFiled: July 22, 2011Date of Patent: January 27, 2015Assignee: Par Pharmaceutical, Inc.Inventors: Steven C. Quay, Peter C. Aprile, Zenaida O. Go, Anthony P. Sileno
-
Publication number: 20140101175Abstract: A method and apparatus that enables a user to sort data from one or more sample lots, which may be obtained via a network, such as the Internet, into a composite parameter structure. The composite parameter structure is a function of one or more parameters corresponding to one or more characteristics associated with one or more sample lots. The composite parameter structure representation may be printed, stored, or transmitted to another location. A server device that is coupled and working in conjunction with a client device may implement the present invention.Type: ApplicationFiled: December 16, 2013Publication date: April 10, 2014Applicant: PAR PHARMACEUTICAL, INC.Inventors: Robert RUEMER, Narayan Ragunathan, Robert A. Femia
-
Patent number: 8620596Abstract: A method and apparatus that enables a user to sort data from one or more sample lots, which may be obtained via a network, such as the Internet, into a composite parameter structure. The composite parameter structure is a function of one or more parameters corresponding to one or more characteristics associated with one or more sample lots. The composite parameter structure representation may be printed, stored, or transmitted to another location. A server device that is coupled and working in conjunction with a client device may implement the present invention.Type: GrantFiled: July 19, 2011Date of Patent: December 31, 2013Assignee: Par Pharmaceutical, Inc.Inventors: Robert Ruemer, Narayan Ragunathan, Robert A. Femia
-
Patent number: 8486891Abstract: An aqueous solution of calcitonin suitable for intranasal administration comprised of calcitonin, chlorobutanol at a concentration of less than 0.4% weight/weight, and water and having a pH of less than 4 with the proviso that benzalkonium chloride is not present in the solution. The aqueous solution of calcitonin can be used to treat osteoporosis, Paget's bone disease and hypercalcemia.Type: GrantFiled: February 10, 2012Date of Patent: July 16, 2013Assignee: Par Pharmaceutical, Inc.Inventors: Steven C. Quay, Jorge C. de Meireles, Arati Deshpande, Zenaida O. Go, Anthony P. Sileno
-
Publication number: 20130143848Abstract: The present invention relates to improving the heart function, the survival and/or the treatment of heart insufficiency using megestrol acetate (Megace®; MA) in patients with heart insufficiency and after a myocardial infarction.Type: ApplicationFiled: January 17, 2013Publication date: June 6, 2013Applicant: PAR PHARMACEUTICALS, INC.Inventor: PAR PHARMACEUTICALS, INC.
-
Patent number: 8383612Abstract: The present invention relates to improving the heart function, the survival and/or the treatment of heart insufficiency using megestrol acetate (Megace®; MA) in patients with heart insufficiency and after a myocardial infarction.Type: GrantFiled: December 1, 2005Date of Patent: February 26, 2013Assignee: Par Pharmaceuticals, Inc.Inventor: Stefan Anker
-
Publication number: 20120190640Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering, intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.Type: ApplicationFiled: July 22, 2011Publication date: July 26, 2012Applicant: PAR PHARMACEUTICALS INC.Inventors: Steven C. QUAY, Peter C. Aprile, Zenaida O. Go, Anthony P. Sileno
-
Patent number: 8138149Abstract: An aqueous solution of calcitonin suitable for intranasal administration comprised of calcitonin, chlorobutanol at a concentration of less than 0.4% weight/weight, and water and having a pH of less than 4 with the proviso that benzalkonium chloride is not present in the solution. The aqueous solution of calcitonin can be used to treat osteoporosis, Paget's bone disease and hypercalcemia.Type: GrantFiled: September 9, 2010Date of Patent: March 20, 2012Assignee: Par Pharmaceutical, Inc.Inventors: Steven C. Quay, Jorge C. de Meireles, Arati Deshpande, Zenaida O. Go, Anthony P. Sileno
-
Patent number: 8003353Abstract: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7% relative to an intramuscular injection of cyanocobalamin with the proviso that the solution is essentially free of mercury and mercury-containing compounds. The present invention is also directed towards a method for elevating the vitamin B12 levels in the cerebral spinal fluid (CSF) comprising administering intranasally a sufficient amount of a mercury-free cyanocobalamin solution so as to increase the average ratio of vitamin B12 in the CSF to that in the blood serum (B12 CSF/B12 Serum×100) to at least about 1.Type: GrantFiled: June 19, 2008Date of Patent: August 23, 2011Assignee: Par Pharmaceutical, Inc.Inventors: Steven C. Quay, Peter C. Aprile, Zenaida O. Go, Anthony P. Sileno